Purification and characterization of monoclonal IgG antibodies recognizing Ebola virus glycoprotein

다국어 초록 (Multilingual Abstract)

Purpose: The goal of this study was to purify and characterize Ebola virus glycoprotein (GP)-specific IgG antibodies from hybridoma clones.
Materials and Methods: For hybridoma production, mice were injected by intramuscular-electroporation with GP DNA vaccines, and boosted with GP vaccines. The spleen cells were used for producing GP-specific hybridoma. Enzyme-linked immunosorbent assay, Western blot assay, flow cytometry, and virus-neutralizing assay were used to test the ability of monoclonal IgG antibodies to recognize GP and neutralize Ebola virus.
Results: Twelve hybridomas, the cell supernatants of which displayed GP-binding activity by enzyme-linked immunosorbent assay and the presence of both IgG heavy and light chains by Western blot assay, were chosen as a possible IgG producer. Among these, five clones (C36-1, D11-3, D12-1, D34-2, and E140-2) were identified to secrete monoclonal IgG antibodies. When the monoclonal IgG antibodies from the 5 clones were tested for their antigen specificity, they recognized GP in an antigen-specific and IgG dose-dependent manner. They remained reactive to GP at the lowest tested concentrations (1.953-7.8 ng/mL). In particular, IgG antibodies from clones D11-3, D12-1, and E140-2 recognized the native forms of GP expressed on the cell surface. These antibodies were identified as IgG1, IgG2a, or IgG2b kappa types and appeared to recognize the native forms of GP, but not the denatured forms of GP, as determined by Western blot assay. Despite their GP-binding activity, none of the IgG antibodies neutralized Ebola virus infection in vitro, suggesting that these antibodies are unable to neutralize Ebola virus infection.
Conclusion: This study shows that the purified IgG antibodies from 5 clones (C36-1, D11-3, D12-1, D34-2, and E140-2) possess GP-binding activity but not Ebola virus-neutralizing activity.

참고문헌 (Reference)

1 Frame KK, "The loss of antibody productivity in continuous culture of hybridoma cells" 35 : 469-476, 1990

2 Qiu X, "Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb" 3 : 3365-, 2013

3 Qiu X, "Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies" 4 : 138ra81-, 2012

4 Roshania R, "Successful implementation of a multicountry clinical surveillance and data collection system for Ebola virus disease in West Africa: findings and lessons learned" 4 : 394-409, 2016

5 이시형, "Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production" 대한백신학회 6 (6): 135-145, 2017

6 Ito H, "Mutational analysis of the putative fusion domain of Ebola virus glycoprotein" 73 : 8907-8912, 1999

7 Brooks GF, "Jawetz, Melnick and Adelberg's medical microbiology" McGraw-Hill 571-573, 2013

8 Strasser JE, "Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs" 182 : 1304-1310, 2000

9 Na W, "Ebola outbreak in Western Africa 2014: what is going on with Ebola virus?" 4 : 17-22, 2015

10 Kohler G, "Continuous cultures of fused cells secreting antibody of predefined specificity" 256 : 495-497, 1975

11 Alvarez CP, "C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans" 76 : 6841-6844, 2002

12 Harlow E, "Antibodies: a laboratory manual" Cold Spring Harbor Laboratory Press 222-223, 1988

13 PREVAIL II Writing Group, "A randomized, controlled trial of ZMapp for Ebola virus infection" 375 : 1448-1456, 2016